California was the first state in the country to require physicians to disclose the FDA status of stem cell therapy. SB 512, signed in 2017, added Section 684 to the Business and Professions Code and obligates any licensed practitioner who performs a non-FDA-approved stem cell therapy to post a notice, display it at the entrance, and hand a written copy to the patient before the first treatment. Two newer laws effective January 1, 2026, AB 1415 and SB 351, do not address stem cells specifically but reshape how any California practice, including a regenerative one, can be owned and managed. This post covers all three.
TLDR: California SB 512 (2017), at Business and Professions Code Section 684, requires a licensed practitioner performing non-FDA-approved stem cell therapy to post a specified notice at the office and entrance, on paper at least 8.5 by 11 inches in no less than 40-point type, and to give the patient a signed written copy before the first therapy. The Medical Board may fine up to $1,000 per violation, but not on a first complaint. Separately, AB 1415 and SB 351 (effective January 1, 2026) expand state oversight of private equity and management arrangements. California’s law is disclosure-only; it does not authorize unapproved therapy the way Florida or Wyoming do. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
If you practice in California and offer any regenerative service, two distinct compliance layers apply at once: the SB 512 disclosure rules, which have been in force since 2018, and the 2026 ownership and oversight laws that govern how your practice is structured. The first is specific to stem cell therapy. The second is not, but it reaches every physician practice in the state, including yours.
Background: What SB 512 Is and Is Not
SB 512, authored by Senator Ed Hernandez and chaptered in 2017, added Section 684 to the Business and Professions Code. It is a disclosure law, not an authorization law. It does not grant permission to perform unapproved stem cell therapy. It says only that if a practitioner chooses to offer such therapy, the practitioner must tell the patient, in a specified way, that the therapy is not FDA-approved. This is the critical distinction from Florida’s SB 1768 and Wyoming’s SF 48, which affirmatively permit physician-performed unapproved therapy under defined conditions. California permits nothing new; it conditions disclosure.
The federal layer sits underneath all of this. No adipose-derived stem cell product is FDA-approved for the orthopedic, pain, or other indications most practices contemplate, and SB 512 does not change that.
The Posting Requirement
A practitioner who performs non-FDA-approved stem cell therapy must display a specified notice in a prominent location visible to patients and post it conspicuously at the office entrance. The statute sets the physical format: the notice must be at least 8.5 by 11 inches and written in no less than 40-point type.
The substance of the notice is that the therapy has not been approved by the FDA and that the patient should consult a primary care provider. Physicians should confirm the exact required wording against the current text of Business and Professions Code Section 684, because statutory notice language is the kind of detail that gets amended and must be reproduced precisely.
A practical point the statute’s plain text raises: the disclosure must reach patients in a form they can understand, which for a practice serving a multilingual patient population means thinking carefully about translation. Confirm the precise multilingual obligation with California counsel rather than assuming a specific percentage threshold, because the operative requirement should be read from the current statute, not a summary of it.
The Written Handout Requirement
Posting is not enough. In addition to the wall notice, the practitioner must provide each patient a written copy of the disclosure before the initial stem cell therapy. The distinction matters: the posted notice is passive, sitting in the entrance and the patient area, while the handout is active, delivered into the patient’s hands before treatment. Best practice, and the approach that survives a Medical Board inquiry, is to have the patient sign and date the written disclosure and to retain that signed copy in the medical record. Treat the signed handout as a documentation gate, the same way you would treat informed consent, which is covered more fully in the discussion of informed consent in regenerative medicine.
Enforcement and Penalties
The penalty structure is narrower than it first appears, and getting it right matters for risk assessment. The licensing board with jurisdiction may cite and fine the practitioner up to $1,000 per violation. But the statute builds in a first-strike grace: no citation or fine issues on the first complaint. Only on a second or subsequent violation may a citation and a fine of up to $1,000 per violation be assessed. So the exposure is real but not the “every encounter is an automatic $1,000” scenario sometimes described. The Medical Board of California also reports on licensees who provide stem cell therapies in its annual reports, which means the practice area carries visibility beyond the individual fine.
How AB 1415 and SB 351 Reshape Practice Structure
Two laws that took effect January 1, 2026, change the ownership and management landscape for every California physician practice, regenerative or not.
AB 1415 expands the Office of Health Care Affordability’s pre-transaction notification regime to cover private equity groups, hedge funds, management services organizations, and newly formed entities created to transact with healthcare entities. In practice, a broad set of deals now requires written notice to OHCA at least 90 days before closing.
SB 351 codifies California’s corporate practice of medicine doctrine as applied to private equity and hedge funds, voids certain contract provisions that let non-clinicians control clinical decisions, restricts some noncompete and non-disparagement terms, and gives the California Attorney General direct enforcement authority.
The practical implication for a regenerative practice: if your stem cell service line sits inside an MSO arrangement, a management agreement, or a private equity-backed structure, that structure must be reviewed for corporate practice of medicine compliance and OHCA reporting obligations before you market or offer the service. These laws are not stem-cell-specific, but they apply to stem cell practices like any other, and the enforcement teeth are new.
California vs. the Authorization States
The states that have legislated in this area fall into different categories, and conflating them is a common error.
| State | Type of law | Posting / notice requirement | Signed consent or handout | Penalty | Effective |
|---|---|---|---|---|---|
| California (SB 512) | Disclosure-only | Yes, 8.5×11, 40-point, posted and at entrance | Yes, written handout before first therapy | Up to $1,000 per violation, not on first complaint | 2018 |
| Florida (SB 1768) | Authorization | Statutory notice in advertisements, sized to the largest type in the ad | Yes, signed consent | Board of Medicine discipline | July 1, 2025 |
| Utah (58-1-512 / SB 275) | Disclosure plus supply chain | Yes, 40-point, posted | Yes, signed consent | Unprofessional conduct / DOPL discipline | 2024, amended 2025 |
| Wyoming (SF 48) | Authorization | Not a posting regime; registration and consent based | Yes, written informed consent | Board action limited; registration required | July 1, 2026 |
The Florida, Utah, and Wyoming frameworks are detailed in the companion overview of why physicians add adipose banking and the broader regulatory picture in FDA regulations for adipose tissue. The inter-state map will sit in the multi-state overview when that post publishes.
Practical Compliance Checklist for California Providers
- Notice posted in a prominent patient-visible location and at the entrance, at least 8.5×11, in no less than 40-point type.
- Notice wording confirmed against the current text of Business and Professions Code Section 684.
- Multilingual obligation confirmed with counsel for your specific patient population.
- Written handout prepared matching the posted disclosure.
- Patient signature and date obtained before the initial therapy, retained in the medical record.
- Practice structure reviewed by California healthcare counsel for corporate practice of medicine compliance under SB 351.
- Any MSO or private equity arrangement reviewed for OHCA reporting obligations under AB 1415.
- Staff trained on the posting, handout, and signature workflow.
Frequently Asked Questions
Does SB 512 let a California physician perform stem cell therapy that the FDA has not approved?
No. SB 512 is a disclosure law. It does not authorize unapproved therapy. It requires that if a practitioner offers such therapy, they disclose the FDA status in the specified manner. Federal law and the medical standard of care still govern whether and how the therapy may be offered.
Is every missing disclosure an automatic $1,000 fine?
No. The statute bars any citation or fine on the first complaint. A fine of up to $1,000 per violation becomes available only on a second or subsequent violation.
Do AB 1415 and SB 351 apply to stem cell practices specifically?
No, they apply to California physician practices generally. But a regenerative practice organized through an MSO or private equity structure is squarely within their scope and must be reviewed for compliance before offering services.
Key Takeaways
California’s SB 512 is the original template that later state laws built on, but it is the most limited kind: pure disclosure. It tells a practitioner who offers unapproved stem cell therapy how to inform the patient, through a posted 40-point notice and a signed written handout retained in the record, and it backs that with a Medical Board fine that does not attach until a second violation. It grants no authorization, which is the line that separates it from Florida and Wyoming. Layered on top for 2026 are AB 1415 and SB 351, which do not mention stem cells but reach every practice’s ownership and management structure and now carry direct Attorney General enforcement on the corporate practice of medicine. A California regenerative practice has to clear both layers, and neither changes the underlying federal reality that no adipose-derived product is approved for these uses or that banking is a preservation decision, not a treatment.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
California physicians weighing how tissue preservation fits a compliant practice can contact Save My Fat to discuss the operational side. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
